Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | HRH2 | P25021 | 4/20 | 0.54 |
| ▸ | HRH1 | P35367 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14006285 | 0.96 | EPHX2 (0.62) | EPHX2LMNATSHRALDH1A1KDM4E | |
| SCHEMBL14006223 | 0.89 | LMNA (0.68) | KCNH2LMNATSHRALDH1A1KDM4E | |
| SCHEMBL14006288 | 0.88 | LMNA (0.70) | EPHX2KCNH2LMNATSHRALDH1A1 | |
| SCHEMBL14006202 | 0.88 | LMNA (0.70) | EPHX2KCNH2LMNATSHRALDH1A1 | |
| SCHEMBL14006284 | 0.86 | EPHX2 (0.60) | EPHX2LMNATSHRALDH1A1KDM4E | |
| SCHEMBL14006283 | 0.84 | CACNA1G (0.62) | CHRNA7KCNH2 | |
| SCHEMBL14006298 | 0.83 | HDAC3 (0.54) | CHRNA7KCNH2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL14006277 | 0.82 | HTR1A (0.59) | CHRNA7KCNH2 | |
| SCHEMBL14006227 | 0.82 | EPHX2 (0.65) | EPHX2KCNH2LMNAALDH1A1MAPT | |
| SCHEMBL14006146 | 0.79 | CHRNA7 (0.51) | CHRNA7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | SIENA BIOTECH S.P.A. (IT) | 2008-11-06 | — | — | US | disclosed |
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | SIENA BIOTECH S.P.A. (IT) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | CHRNA7, CHRNA5, CHRNA1 | EPHX2 777/4885CHRNA7 1/4885KCNH2 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.